The research team, led by Naoya Kase and Yohsuke Harada, tackled a technical problem that has hampered the field for years. The defining feature of a regulatory T cell is its expression of a transcription factor called Foxp3, the master switch that establishes and maintains the cell’s identity. But if you experimentally delete the Foxp3 gene to study what happens, the protein disappears, and along with it any reliable way to label and track the cell. Conventional markers fail, and the cell becomes essentially invisible to the tools immunologists normally use to isolate specific cell populations for analysis.

To solve this, the researchers engineered a clever workaround using a bacterial artificial chromosome transgene. This engineered DNA segment drives expression of three useful proteins, green fluorescent protein, luciferase, and the diphtheria toxin receptor, under the control of the Foxp3 promoter. Crucially, this reporter operates independently of the endogenous Foxp3 locus, so even after the native gene is deleted with tamoxifen, the cells continue to glow green. The team validated the system carefully, showing that after tamoxifen treatment the frequency of cells detectable by antibody staining for Foxp3 dropped sharply while the fluorescent population persisted, and that most fluorescent cells retained canonical Treg features such as high CD25 expression and enriched CTLA-4.

The mouse model at the heart of the study is distinctive in another important respect. Rather than inducing eczema-like disease with an external chemical irritant, as in the widely used MC903 model, the researchers deleted two genes, Foxp3 and Bcl6, whose combined loss triggers spontaneous development of atopic dermatitis-like skin inflammation roughly two weeks after deletion. That timing window is a major advantage, because it allows scientists to observe molecular changes in immune cells as they unfold before any visible disease appears, something impossible in models where dermatitis erupts almost immediately.

When the team sequenced the RNA of fluorescent cells sorted from the spleens of these mice fourteen days after starting tamoxifen treatment, the results contained a genuine surprise. The combined deletion produced a signature of 144 genes specifically upregulated in the double-deficient Tregs, and gene ontology analysis revealed an unexpectedly strong enrichment of antiviral and type I interferon response programs. Type I interferons are classically associated with the body’s first line of defense against viruses, not with the type 2 allergic inflammation that defines eczema. Further gene set enrichment analysis comparing single and double knockout cells confirmed the pattern, and most interferon-alpha response genes showed their highest expression in the double-deficient group.

The researchers then asked whether Bcl6 loss alone could explain the interferon signature, since BCL6 is known to act as a transcriptional repressor that tamps down antiviral programs in other immune cell types. Reanalysis of an existing public dataset comparing Bcl6-deficient and wild-type Tregs showed that the interferon-related gene ontology terms were not significantly enriched in Tregs lacking only Bcl6. This indicated that losing Bcl6 by itself is not enough. Instead, the simultaneous disruption of both Foxp3-dependent and Bcl6-dependent transcriptional control appears to create a permissive state in which the interferon-associated program can emerge in this cell lineage.

The pivotal question was whether this mouse signature had any bearing on actual human disease. To find out, the team reanalyzed publicly available single-cell RNA sequencing data from the peripheral blood of atopic dermatitis patients and healthy controls. After careful quality control, batch correction with Harmony, and clustering of the T cell compartment into nine distinct subsets, they converted 102 of the mouse signature genes into their human orthologs and computed signature scores for each cell type. The result was striking: the mouse-derived signature was substantially and selectively elevated in the regulatory T cell population of patients, while other T cell subsets showed far less enrichment. A parallel analysis using a canonical type I interferon response gene set produced the same disease-specific pattern in Tregs.

Digging deeper into the regulatory architecture, the researchers used a computational tool called ChEA3 to identify upstream transcription factors likely driving the upregulated genes, and then applied SCENIC, a single-cell regulatory network inference method, to the patient data. Nine of the top twenty predicted factors could be detected as active regulons in human Tregs, and most of these were preferentially enriched in patient cells compared with healthy controls. The standouts were a coherent cast of interferon-associated regulators: IRF7, IRF9, STAT1, and STAT2, along with BATF3. This network maps precisely onto the canonical type I interferon pathway, in which interferon signaling through the JAK-STAT cascade assembles an ISGF3 complex of STAT1, STAT2, and IRF9 to activate interferon-stimulated genes, with IRF7 serving as a key amplifier of the antiviral program.

Context matters enormously here, and the authors are careful on this point. Type I interferons have a complicated relationship with atopic dermatitis. Patients with eczema are famously susceptible to viral skin infections such as eczema herpeticum, and plasmacytoid dendritic cells, the skin’s major interferon producers, are markedly reduced in diseased skin. Animal work has even shown that interferon produced by a specific monocyte subset suppresses type 2 inflammation in eczema-like disease. Yet prior studies in other settings, including rhinovirus infection and chronic immune thrombocytopenia, have found that Tregs acquiring an interferon-responsive transcriptional state lose suppressive capacity. The new findings suggest that interferon-related responses in atopic dermatitis may differ sharply between cell types, with Tregs shifting into an interferon-high state even as antiviral defense elsewhere is weakened. Whether this program actually causes Treg dysfunction in patients remains unproven, since suppressive activity was not directly measured in the human cells analyzed.

The study carries clear limitations that temper its conclusions. About ten percent of the fluorescent cells in untreated mice were Foxp3-negative, so a minor non-Treg contribution to the profiles cannot be excluded. The fluorescent cells were detected in inflamed skin, but their causal role in driving dermatitis was not established, and the human analysis was restricted to atopic dermatitis, leaving open whether the interferon-high Treg state is unique to eczema or common across inflammatory skin diseases. Even so, the work delivers something the field has lacked: a genetically defined, temporally controllable animal model whose Treg transcriptional state, upstream regulators and all, mirrors what is found in patient cells. If future experiments confirm that this interferon-associated state drives functional defects in Tregs, it could open a genuinely new therapeutic angle for a disease currently dominated by antibody drugs that carry ocular side effects and heavy costs.

Subject of Research: Type I interferon-associated transcriptional changes in regulatory T cells in atopic dermatitis

Article Title: Cross-species gene expression analysis identifies a type I interferon-associated transcriptional signature in Tregs from atopic dermatitis

Article References: Cross-species gene expression analysis identifies a type I interferon-associated transcriptional signature in Tregs from atopic dermatitis. (n.d.). https://doi.org/10.3389/jcia.2026.17310

Image Credits: AI Generated

DOI: 10.3389/jcia.2026.17310

Keywords: atopic dermatitis, regulatory T cells, Foxp3, Bcl6, type I interferon, transcriptional signature, single-cell RNA sequencing, IRF7, STAT1, mouse model, immune tolerance, eczema